Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
Olaparib+Trastuzumab in HER2[+] Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer

This is a multicenter, open-label, single-arm, phase II clinical trial, phase II trial will evaluate the efficacy and safety of olaparib plus trastuzumab in patients with HER2[+], BRCA-mutated advanced breast cancer

measurable disease
olaparib
urine test
herceptin
platelet count
  • 6 views
  • 27 Jan, 2021
  • 27 locations
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Efficacy Study of Single Agent Trastuzumab or Lapatinib to Treat HER2-Overexpressing Breast Cancer

This study will evaluate the activity of single agent trastuzumab or lapatinib in patients not previously treated for HER-2 positive (FISH positive) metastatic breast cancer. A companion

measurable disease
kidney function tests
breast cancer
immunological adjuvant
progesterone
  • 1 views
  • 07 Nov, 2020
  • 1 location
A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer

This is a Phase II, randomized, multicenter, 2-arm, open-label clinical trial designed to compare the safety and efficacy of RC48-ADC with that of capecitabine + lapatinib in participants with

measurable disease
EGFR
breast cancer
epidermal growth factor
capecitabine
  • 128 views
  • 15 Mar, 2021
  • 43 locations
Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+ HER2+ Advanced Breast Cancer Patients

better PFS than ET alone (TAnDEM trial and trial comparing lapatinib plus letrozole versus letrozole alone) [2],[3] confirming existence of cross talk between ER and HER2 pathways in clinical setting

estrogen receptor
breast cancer
her2/neu-positive breast cancer
palbociclib
abemaciclib
  • 0 views
  • 26 Jan, 2021
  • 1 location
A Study to Evaluate the Efficacy and Safety of Margetuximab Plus Chemotherapy in the Treatment of Chinese Patients With HER2+ MBC

This is a randomized, open-label, multi-center, Phase II clinical study to evaluate the efficacy and safety of margetuximab plus chemotherapy compared with trastuzumab plus chemotherapy in Chinese patients (Mainland, Hong Kong and Taiwan) with advanced HER2+ breast cancer who have received at least 2 prior lines of anti-HER2 directed therapy …

measurable disease
breast cancer
capecitabine
platelet count
liver metastasis
  • 3 views
  • 23 Jan, 2021
  • 1 location
CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma

In chordoma cell lines and patient biopsies, the p16 (CDKN2A) tumor suppressor is consistently deleted. Thus, chordomas are an example of a tumor with universal activation of the cyclin-dependent kinases 4 and 6 (CDK4/6) pathway, and experiments with patient-derived chordoma cell lines demonstrate aberrant CDK4/6 activity downstream of p16 loss …

hysterectomy
sorafenib
palbociclib
vasectomy
metastatic chordoma
  • 33 views
  • 21 Jan, 2021
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

This is a Phase I/II, open-label dose-escalation study designed to evaluate the maximum tolerated dose (MTD) and dose-limiting side effects of ibrutinib (560 or 840 or 420 mg daily oral dose), given in combination with trastuzumab administered through the vein, in patients with HER2-amplified Metastatic Breast Cancer that has gotten …

cancer
breast cancer
growth factor
stage iv breast cancer
muga scan
  • 36 views
  • 10 Mar, 2021
  • 1 location
Selective Treatment According to Molecular Subtype of Prostate Cancer

This is an open-label study that includes three substudies of random distribution. First, a sample of the primary tumor will be obtained and will be analyzed by an immunohistochemical technique to determine several markers. Depending on the expression of these markers, the patients will be characterize as group 1 (Luminal …

serum testosterone
testosterone
  • 1 views
  • 22 Jan, 2021
  • 1 location
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC

BACKGROUND: Gastric cancer is one of the most common cancers and is one of the most deadly cancers. Most patients have advanced disease and should receive first-line trastuzumab-associated chemotherapy when the biopsy is positive for immunocytochemical expression and / or HER2 gene amplification. A study conducted by our group noted …

  • 0 views
  • 03 Feb, 2021
  • 1 location